Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aim: To assess the effects of once‐weekly exenatide on 24‐hour glucose control and variability. Materials and methods: This double‐blind, placebo‐controlled trial randomized metformin‐treated adults with type 2 diabetes to once‐weekly exenatide 2.0 mg or placebo. Continuous glucose monitoring ( CGM ) was performed at baseline and weeks 4 and 10. The primary outcome was change in CGM ‐measured 24‐hour mean glucose level. Results: In the once‐weekly exenatide (n = 60) and placebo (n = 56) groups (modified intention‐to‐treat population), the baseline glycated haemoglobin ( HbA1c ) concentrations were 8.2% and 8.0%, respectively, and the fasting plasma glucose ( FPG ) concentration was 9.86 and 9.32 mmol/ L , respectively. Once‐weekly exenatide significantly (p < 0.001) reduced 24‐hour mean glucose level versus placebo (week 4, −1.44 vs −0.29 mmol/ L ; week 10, −1.71 vs −0.17 mmol/ L ), with consistent control throughout the week. Once‐weekly exenatide significantly reduced FPG and 2‐hour postprandial glucose ( PPG ) levels versus placebo at week 4 ( FPG , −1.65 vs −0.11 mmol/ L ; PPG , −1.79 vs −0.11 mmol/ L ) and week 10 ( FPG , −2.32 vs −0.28 mmol/ L ; PPG , −2.46 vs −0.33 mmol/ L ). At week 10, once‐weekly exenatide reduced the mean amplitude of glucose excursions ( MAGE ; −0.84 vs 0.16 mmol/ L ) and standard deviation (s.d.) of mean glucose (−0.35 vs 0.04 mmol/ L ). By week 10, once‐weekly exenatide‐treated participants spent more time in euglycaemia (once‐weekly exenatide, 77% vs placebo, 58%), less time in hyperglycaemia (22% vs 42%), and a similar time in hypoglycaemia (0.7% vs 0.3%). Common adverse events were injection‐site nodule (once‐weekly exenatide, 10.0% vs placebo, 0.0%), urinary tract infection (6.7% vs 8.9%) and nausea (6.7% vs 0.0%). Conclusions: In metformin‐treated participants with type 2 diabetes, once‐weekly exenatide significantly improved daily glucose control and reduced glycaemic variability at weeks 4 and 10, as shown by reductions in 24‐hour glucose, FPG and PPG levels, MAGE and s.d., and increased time spent in euglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Glycemic Variability: How Do We Measure It and Why Is It Important?
Suh, S., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.273 · Cited by 439
Nalysnyk, L., Hernandez‐Medina, M., & Krishnarajah, G. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01160.x · Cited by 343 · cited 1×
“genesis of diabetes complications, suggesting that glycaemic variability should also be considered a target for glucose-lowering therapies.(6,7) Glycaemic variability refers to acute excursions in blood glucose levels, including hypoglycaemic events and postprandial”
BackgroundBergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Grimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C. T., Dong, H., & Malloy, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2660 · Cited by 63
Cited by
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Glycemic variability: adverse clinical outcomes and how to improve it?
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01085-6 · Cited by 255
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
Newbold, R., Benedetti, A., Kimoff, R. J., Meltzer, S., Garfield, N., Dasgupta, K., Gagnon, R., Lavigne, L., Olha, A., Rey, E., et al. (2021) · Chest · doi:10.1016/j.chest.2020.07.014 · Cited by 28
Metadata
- Authors
- Frías, J. P., Nakhle, S., Ruggles, J. A., Zhuplatov, S., Klein, E., Zhou, R., & Strange, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-09-21
- Volume
- 19
- Issue
- 1
- Pages
- 40-48
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2507708274
- Cited by
- 28
- References
- 6
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/dom.12763
- The paper
- Frías, J. P., Nakhle, S., Ruggles, J. A., Zhuplatov, S., Klein, E., Zhou, R., & Strange, P. (2017). Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.